Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases.

Pantherna’s innovative technology platform has a focus on developing advanced nanoparticle solutions for the delivery and expression of mRNA therapeutics in the vascular endothelium. We are based in Hennigsdorf in the state of Brandenburg with laboratory facilities at the Bayer AG CoLaborator in Berlin, Germany.


Our mission

Delivery technology-driven

mRNA-based drug development


Pantherna´s mRNA therapies are based on its two fundamental technology pillars, PTXmRNA™ and PTX_LNP™, enabling robust expression of the desired protein in the correct clinical setting in order to exploit its therapeutic potential.

read more


Our current focus is the development of a systemic mRNA therapy for pulmonary edema by restoring endothelial cell function in the lung via expression of therapeutic proteins for vascular barrier stabilization in a highly spatial manner.

read more


Pantherna Therapeutics is open to all types of collaborations with pharmaceutical and biotech companies.We wish to partner our in-house development programs at the pre-clinical or clinical stage.

read more

Public funding


Pantherna is supported by public funding from the EU (EFRE). EFRE is provided by the State Brandenburg  through the program “ProFIT”:


#80258140/ 41 ProFIT:  „Vaskularspezifische Transportsysteme für Nukleinsäure in 16761 Hennigsdorf, Neuendorfstraße 20b“

Get in touch


    Innovationsforum Hennigsdorf
    Neuendorfstrasse 20b
    D-16761 Hennigsdorf

    Phone +49(0)3302-202 240-0
    Fax: +49(0)3302-202 240-1


    Bayer AG CoLaborator Berlin
    Müllerstrasse 178
    D-13353 Berlin


    Phone +49 (0)30 4072 370-0